SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on April 17, 2003; DOI 10.1182/blood-2003-01-0117. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-01-0117v1 102/4/1529    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bradai, M. Articles by de Montalembert, M. Search for Related Content PubMed PubMed Citation Articles by Bradai, M. Articles by de Montalembert, M. Related Collections Red Cells Gene Expression Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 August 2003, Vol. 102, No. 4, pp. 1529-1530 RED CELLS Brief report Hydroxyurea can eliminate transfusion requirements in children with severe -thalassemia Mohamed Bradai, Mohand Tayeb Abad, Serge Pissard, Fatima Lamraoui, Laurent Skopinski, and Mariane de Montalembert From the Service d'Hématologie, Hôpital Franz Fanon, Blida, Algeria; Laboratoire de Génétique Moléculaire and Institut National de la Santé etdela Recherche Médicale (INSERM) U 468, Hôpital Henri Mondor, Créteil, France; and Service de Pédiatrie Générale, Hôpital Necker-Enfants Malades, Paris, France. Hydroxyurea (HU) enhances fetal hemoglobin (Hb) production. An increase in total Hb level has been repeatedly reported during HU treatment in patients with sickle cell disease and in several patients with -thalassemia intermedia. Effects in patients with -thalassemia major are controversial. We now report a marked elevation of total Hb levels with HU that permitted regular transfusions to be stopped in 7 children with transfusion-dependent -thalassemia. The median follow-up was 19 ± 3 months (range, 13-21 months). We conclude that HU can eliminate transfusional needs in children with -thalassemia major, which could be particularly useful in countries such as Algeria, where supplies of blood or chelating agents are limited. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. Bianchi, C. Zuccato, I. Lampronti, M. Borgatti, and R. Gambari Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of -Thalassemia and Sickle-Cell Anemia Evid. Based Complement. Altern. Med., December 11, 2007; (2007) nem139v1. [Abstract] [Full Text] [PDF] A. Mai, K. Jelicic, D. Rotili, A. Di Noia, E. Alfani, S. Valente, L. Altucci, A. Nebbioso, S. Massa, R. Galanello, et al. Identification of Two New Synthetic Histone Deacetylase Inhibitors That Modulate Globin Gene Expression in Erythroid Cells from Healthy Donors and Patients with Thalassemia Mol. Pharmacol., November 1, 2007; 72(5): 1111 - 1123. [Abstract] [Full Text] [PDF] A. Banerjee, S. B. Chakrabarty, S. R. Karmakar, A. Chakrabarty, S. J. Biswas, S. Haque, D. Das, S. Paul, B. Mandal, B. Naoual, et al. Can Homeopathy Bring Additional Benefits to Thalassemic Patients on Hydroxyurea Therapy? Encouraging Results of a Preliminary Study Evid. Based Complement. Altern. Med., October 29, 2007; (2007) nem161v1. [Abstract] [Full Text] [PDF] D. Rund and E. Rachmilewitz {beta}-Thalassemia N. Engl. J. Med., September 15, 2005; 353(11): 1135 - 1146. [Full Text] [PDF] B. Gulbis, D. Haberman, D. Dufour, C. Christophe, C. Vermylen, F. Kagambega, F. Corazza, C. Devalck, M.-F. Dresse, K. Hunninck, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience Blood, April 1, 2005; 105(7): 2685 - 2690. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020